RARE BRAIN TUMOR
TREATMENTS
GBM, IDH-mutant gliomas, ependymoma, and primary CNS lymphoma โ understand what Chinese neuro-oncology programmes offer for international patients, from cost-accessible temozolomide to IDH inhibitor trials and SPHIC particle therapy.
Molecular Classification Guides Treatment
Brain tumour treatment follows WHO 2021 classification integrating IDH mutation status, TERT promoter mutation, 1p/19q codeletion, MGMT promoter methylation, EGFR amplification, and CDKN2A/B deletion. These molecular features directly determine prognosis and treatment strategy.
MGMT Methylation in GBM
MGMT promoter methylation silences DNA repair in ~40โ50% of GBM, making tumours more sensitive to temozolomide. Methylated GBM: median OS ~22โ23 months. Unmethylated: ~12โ14 months.
IDH Mutation Status
IDH mutation separates favourable IDH-mutant gliomas from aggressive IDH-wildtype GBM. 1p/19q codeletion defines oligodendroglioma. These distinctions directly change treatment approach.
Key Treatment Options in China
GBM: Stupp Protocol and TTFields
Maximal safe resection followed by concurrent temozolomide 75 mg/mยฒ plus radiotherapy (60 Gy/30 fractions), then adjuvant temozolomide for 6 cycles. TTFields (Optune) available in China. Temozolomide at substantially lower cost than Western markets.
IDH Inhibitors for Recurrent Glioma
Vorasidenib (combined IDH1/2 inhibitor, CNS-penetrant) received FDA approval in 2024 for Grade 2 IDH-mutant glioma. NMPA review in process. Chinese clinical trials evaluating IDH inhibitors for recurrent disease.
Bevacizumab for Recurrent GBM
Approved for recurrent GBM, reduces vasogenic oedema. Chinese biosimilars available at substantially lower cost than originator bevacizumab.
Proton/Carbon Ion Therapy at SPHIC
SPHIC treats skull base chordoma, chondrosarcoma, spinal sarcomas, selected paediatric brain tumours, and select GBM cases. JCI-accredited. Cost substantially lower than Japan or Europe.
Primary CNS Lymphoma
High-dose methotrexate plus rituximab plus temozolomide followed by autologous SCT consolidation. CAMS and PKUPH haematology/neuro-oncology programmes provide full treatment capability.
EGFR-Amplified GBM: Emerging Targeted Therapy
EGFR is amplified or mutated (EGFRvIII) in ~50โ60% of GBM. Conventional EGFR inhibitors lack adequate CNS penetration. Novel CNS-penetrant EGFR inhibitors and bispecific approaches are in Phase I/II trials at Chinese academic centres โ the most active targeted programme for EGFR-amplified GBM.
Benefits and Limitations
Benefits
- Cost-accessible GBM standard treatment (temozolomide, bevacizumab biosimilars)
- IDH inhibitor access for IDH-mutant recurrent gliomas
- SPHIC particle therapy for skull base and paediatric cases
- EGFR-directed trial access for EGFR-amplified GBM
Limitations
- GBM median OS of 14โ16 months even with best available treatment
- Highly infiltrative, treatment-resistant tumour biology
- Realistic expectations essential for all GBM treatment decisions
When to Consider This Option
Temozolomide Cost Barrier
GBM standard treatment unaffordable domestically โ Chinese commercial access.
IDH-Mutant Recurrent Glioma
IDH inhibitor or vorasidenib trial access at Chinese academic centres.
Skull Base or Paediatric Tumours
Proton therapy evaluation at SPHIC.
EGFR-Amplified GBM
Failed standard therapy; EGFR-directed trial access is the objective.
Frequently Asked Questions
About Brain Tumour Treatment
How CancerFax Helps
CancerFax is a specialist cancer access and patient-navigation platform. We help patients and families understand their options, organise medical records, coordinate hospital communication, and support cross-border treatment planning where appropriate.
We help collect and organise reports, scans, pathology, biomarker results, and treatment history for structured case review.
We communicate with hospitals or trial teams to assess whether a case may be suitable for further screening.
We support appointment coordination, document submission, translation, and direct communication with international departments.
For international patients, we help with practical coordination โ travel planning, hospital admission guidance, and local support.
If this option is not suitable, we help explore other relevant treatments, clinical trials, or advanced care pathways.
From inquiry through to follow-up, our coordinators provide a single point of contact for the family.
CancerFax does not guarantee treatment access, eligibility, or clinical outcome. Our role is to help patients access accurate information, structured review, and appropriate specialist pathways.
Exploring Brain Tumour Treatment Options?
CancerFax connects brain tumour patients with cost-accessible standard therapy, IDH inhibitor trial access, and SPHIC particle therapy at Chinese academic centres.
This content is for informational purposes only and does not constitute medical advice. Always consult a qualified oncologist before making treatment decisions.